Skip to content

Study · In vitro (cells) · 1996

3 results

Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hMC1R.

Haskell-Luevano C, Miwa H, Dickinson C, Hadley ME, Hruby VJ, Yamada T, Gantz I

Journal of medicinal chemistry1 Jan 1996Cited by 41 (Europe PMC)

PMID8558511 (opens in a new tab)DOI10.1021/jm950407s (opens in a new tab)PepBankPUB-08558511
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cells expressing hMC1R, 86% of MT-II remained bound 6 h after ligand removal, versus 25% for alpha-MSH and 65% for MT-I.

    In plain wordsIn cells, MT-II stayed attached to its receptor longer than alpha-MSH and MT-I six hours after removal.

    Peptide
    Melanotan II
    Outcome
    Not applicablePeptide remaining bound to hMC1R 6 h after ligand removal
    Study

    humann: not reported in source

    Human melanocortin receptor hMC1R
    Comparator
    alpha-MSH and MT-I
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Peptide bound after 6 h
    86%
    MT-II, hMC1R

    Source sentences

    Summary
    alpha-MSH remained 25% bound, MT-I 65% bound, and MT-II 86% bound 6 h after the ligand had been removed from the assay medium.
    1 context sentence
    Summary · context
    We have examined the differences in their relative dissociation rates from the melanocortin receptor, hMC1R, to try and correlate peptide dissociation rates with the observations of prolonged biological activity.
  2. 02LabIn vitro (cells)Activity measurement

    In cells expressing hMC1R, the dissociation rate of MT-II was 4 times slower than that of alpha-MSH.

    In plain wordsIn cells, MT-II came off its receptor 4 times more slowly than alpha-MSH did.

    Peptide
    Melanotan II
    Outcome
    DecreaseRelative dissociation rate from hMC1R versus alpha-MSH
    Study

    humann: not reported in source

    Human melanocortin receptor hMC1R
    Comparator
    alpha-MSH
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The relative dissociation rate of MT-II was 4 times slower than that for alpha-MSH and 2 times slower than that for MT-I, which was 2 times slower than that for alpha-MSH.
    1 context sentence
    Summary · context
    We have examined the differences in their relative dissociation rates from the melanocortin receptor, hMC1R, to try and correlate peptide dissociation rates with the observations of prolonged biological activity.
  3. 03LabIn vitro (cells)Activity measurement

    In cells expressing hMC1R, the dissociation rate of MT-II was 2 times slower than that of MT-I.

    In plain wordsIn cells, MT-II came off its receptor 2 times more slowly than MT-I did.

    Peptide
    Melanotan II
    Outcome
    DecreaseRelative dissociation rate from hMC1R versus MT-I
    Study

    humann: not reported in source

    Human melanocortin receptor hMC1R
    Comparator
    MT-I
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The relative dissociation rate of MT-II was 4 times slower than that for alpha-MSH and 2 times slower than that for MT-I, which was 2 times slower than that for alpha-MSH.
    1 context sentence
    Summary · context
    We have examined the differences in their relative dissociation rates from the melanocortin receptor, hMC1R, to try and correlate peptide dissociation rates with the observations of prolonged biological activity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.